Technology area: Biotechnology & Pharmaceuticals
31 pending office actions • 21 art units • 29 examiners • 0 of 31 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Baylor College of Medicine has 34 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 32 distinct examiners and 23 distinct art units. The examiner figure is close to the pending-action figure, showing broad examiner distribution, while the art-unit figure reflects repeated activity within some units.
BARRON, SEAN C is the busiest examiner, with 2 pending matters. That examiner has the largest identified workload, but the figure remains small relative to the portfolio's total pending actions. Most prosecution work is therefore distributed across other examiner assignments.
The profile supports a portfolio process built around art-unit tracking, shared technical positions, and examiner-specific response preparation. Counsel should use the repeated art-unit assignments to identify recurring issues without assuming that the same examiner approach will apply across the docket.
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (16%) |
| §103 only | 6 (19%) |
| §102 only | 1 (3%) |
| §112 only | 2 (6%) |
| Double-patenting + other | 5 (16%) |
| Multi-statute (no §101) | 12 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOLOYE, TITILAYO | 2 | 62.3% | +48.3% |
| BARRON, SEAN C | 2 | 52.7% | +30.4% |
| ARIANI, KADE | 1 | 75.0% | +32.0% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
| KLINKEL, KORTNEY L | 1 | 39.7% | +43.1% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| HILL, MYRON G | 1 | 66.1% | +20.7% |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
| NOBLE, MARCIA STEPHENS | 1 | 67.2% | +39.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245281 | CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS | BUTTICE, AUDREY L | 119d overdue |
| 17973738 | DEVICES, SYSTEMS, AND METHODS FOR DIAGNOSING TREATING AND MONITORING CHRONIC PELVIC PAIN | TOTH, KAREN E | 91d overdue |
| 16971992 | TISSUE ANALYSIS BY MASS SPECTROMETRY | GODDARD, LAURA B | 71d overdue |
| 18301048 | TARGETING OF SRC-3 IN IMMUNE CELLS AS AN IMMUNOMODULATORY THERAPEUTIC FOR THE TREATMENT OF CANCER | DIBRINO, MARIANNE | 19d overdue |
| 18261983 | BONE-SPECIFIC DELIVERY OF POLYPEPTIDES | DUNN, LINDSAY MICHELLE | 17d overdue |
| 17906490 | SARS-COV2-SPECIFIC T CELL COMPOSITIONS AND THEIR USE IN TREATING AND PREVENTING CORONAVIRUS AND OTHER RESPIRATORY VIRUS INFECTIONS | BARRON, SEAN C | 8d |
| 17995540 | DAILY LIVING MONITORING AND MANAGEMENT SYSTEM | EPPERT, LUCY CLARE | 20d |
| 18726702 | RXR AGONISTS IN EYE DISORDERS | INAM, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906490 | SARS-COV2-SPECIFIC T CELL COMPOSITIONS AND THEIR USE IN TREATING AND PREVENTING CORONAVIRUS AND OTHER RESPIRATORY VIRUS INFECTIONS | BARRON, SEAN C | 8d |
| 18276164 | Engineered NKT Cells for Expansion and In Vivo Preservation and Methods of Use for the Control of Tumor Cells | NOBLE, MARCIA STEPHENS | 71d |
| 18960342 | DEVELOPMENT OF AMYLOGLUCOSIDASE AS A MEDICINAL FOOD OR DIETARY SUPPLEMENT | ARIANI, KADE | — |
| 18740824 | NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME | WEHBE, ANNE MARIE SABRINA | — |
| 18664964 | SMALL MOLECULE BTK DEGRADERS AND METHODS OF USE THEREOF | KLINKEL, KORTNEY L | — |
| 18282730 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | HILL, MYRON G | — |
| 18465333 | COMPOSITONS AND METHODS FOR USE OF KALIUM CHANNEL RHODOPSINS | POPA, ILEANA | — |
| 18449841 | Targeting the Tumor Microenvironment Using Manipulated NKT Cells | MOLOYE, TITILAYO | — |
| Art Unit | Apps |
|---|---|
| 1632 | 3 |
| 1634 | 2 |
| 1627 | 2 |
| 1671 | 2 |
| 1644 | 2 |
| 1625 | 2 |
| 1641 | 2 |
| 3791 | 2 |
| 1653 | 2 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18960342 | DEVELOPMENT OF AMYLOGLUCOSIDASE AS A MEDICINAL FOOD OR DIETARY SUPPLEMENT | ARIANI, KADE | 1651 | §102§103§112DP | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18726702 | RXR AGONISTS IN EYE DISORDERS | INAM, SAHAR | 1622 | §102§103§112 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18740824 | NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME | WEHBE, ANNE MARIE SABRINA | 1634 | §102§103§112Other | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18664964 | SMALL MOLECULE BTK DEGRADERS AND METHODS OF USE THEREOF | KLINKEL, KORTNEY L | 1627 | §102§103 | Non-Final OA | — | Pending | May 15, 2024 |
| 18570949 | METHODS FOR IN VIVO DELIVERY OF MICROBES TO HUMAN MICROENVIRONMENTS | BAEK, JONGHWAN NMN | 1618 | §102§103§112DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18282730 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | HILL, MYRON G | 1671 | §102§103§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18465333 | COMPOSITONS AND METHODS FOR USE OF KALIUM CHANNEL RHODOPSINS | POPA, ILEANA | 1633 | §101§103§112 | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18449841 | Targeting the Tumor Microenvironment Using Manipulated NKT Cells | MOLOYE, TITILAYO | 1632 | §112 | Final Rejection | — | Pending | Aug 15, 2023 |
| 18276164 | Engineered NKT Cells for Expansion and In Vivo Preservation and Methods of Use for the Control of Tumor Cells | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | 71d | Pending | Aug 07, 2023 |
| 18262037 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | RAO, PADMAJA S | 1627 | §102§112 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18261983 | BONE-SPECIFIC DELIVERY OF POLYPEPTIDES | DUNN, LINDSAY MICHELLE | 1644 | §102§103§112 | Final Rejection | 17d overdue | Pending | Jul 18, 2023 |
| 18039661 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | 14d | Pending | May 31, 2023 |
| 18301048 | TARGETING OF SRC-3 IN IMMUNE CELLS AS AN IMMUNOMODULATORY THERAPEUTIC FOR THE TREATMENT OF CANCER | DIBRINO, MARIANNE | 1641 | §103§112 | Final Rejection | 19d overdue | Pending | Apr 14, 2023 |
| 18245281 | CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 119d overdue | Pending | Mar 14, 2023 |
| 18018552 | UNIVERSAL ANTIGEN-SPECIFIC T CELL BANKS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY | KELLY, ROBERT M | 1638 | §103 | Final Rejection | 16d | Pending | Jan 28, 2023 |
| 18017302 | DESIGN OF 3D-PRINTED NASOPHARYNGEAL SWABS | PHAM, KATHERINE-PH MINH | 3781 | §103 | Non-Final OA | 10d overdue | Pending | Jan 20, 2023 |
| 18017298 | VAGINAL STENT | DUBOSE, LAUREN | 3771 | §102§103§112 | Non-Final OA | — | Pending | Jan 20, 2023 |
| 18004194 | GENE THERAPY FOR STXBP1 ENCEPHALOPATHY | MOLOYE, TITILAYO | 1632 | §102§103 | Non-Final OA | — | Pending | Jan 04, 2023 |
| 17999408 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | RZECZYCKI, PHILLIP MATTHEW | 1625 | §102Other | Non-Final OA | — | Pending | Nov 21, 2022 |
| 17997161 | TREATMENT AND PREVENTION OF CANCER USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | CHATTIN, AMY MARIE | 1643 | §103DP | Non-Final OA | 73d overdue | Pending | Oct 26, 2022 |
| 17973738 | DEVICES, SYSTEMS, AND METHODS FOR DIAGNOSING TREATING AND MONITORING CHRONIC PELVIC PAIN | TOTH, KAREN E | 3791 | §101§112 | Non-Final OA | 91d overdue | Pending | Oct 26, 2022 |
| 17997171 | TREATMENT AND PREVENTION OF ALLOREACTIVITY USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | DAHLE, CHUN WU | 1641 | §112DP | Final Rejection | 3d overdue | Pending | Oct 26, 2022 |
| 17995540 | DAILY LIVING MONITORING AND MANAGEMENT SYSTEM | EPPERT, LUCY CLARE | 3791 | §101§103§112 | Final Rejection | 20d | Pending | Oct 05, 2022 |
| 17906490 | SARS-COV2-SPECIFIC T CELL COMPOSITIONS AND THEIR USE IN TREATING AND PREVENTING CORONAVIRUS AND OTHER RESPIRATORY VIRUS INFECTIONS | BARRON, SEAN C | 1653 | §101§102§103Other | Non-Final OA | 8d | Pending | Sep 16, 2022 |
| 17855322 | ADENOVIRAL- BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS | MARVICH, MARIA | 1634 | §103§112Other | Non-Final OA | — | Pending | Jun 30, 2022 |
| 17635197 | THIRD PARTY VIRUS-SPECIFIC T CELL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME IN ANTI-VIRAL PROPHYLAXIS | BARRON, SEAN C | 1653 | §102§112 | Final Rejection | — | Pending | Feb 14, 2022 |
| 17576597 | DENDRITIC CELL IMMUNOTHERAPY | JUEDES, AMY E | 1644 | §103§112DP | Non-Final OA | 132d overdue | Pending | Jan 14, 2022 |
| 17593747 | MULTI-RESPIRATORY VIRUS ANTIGEN-SPECIFIC T CELLS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY | ALLEN, MICHAEL D | 1671 | §103 | Final Rejection | 27d | Pending | Sep 23, 2021 |
| 17287972 | ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY | BATES, KEENAN ALEXANDER | 1631 | §103 | Non-Final OA | 44d overdue | Pending | Apr 22, 2021 |
| 17050341 | CAR T CELLS WITH ONE OR MORE INTERLEUKINS | CHASE, CAROL ANN | 1646 | §103 | Final Rejection | — | Pending | Oct 23, 2020 |
| 16971992 | TISSUE ANALYSIS BY MASS SPECTROMETRY | GODDARD, LAURA B | 1642 | §101§103 | Final Rejection | 71d overdue | Pending | Aug 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBaylor College of Medicine has 31 pending office actions as of October 2026, spread across 21 art units and 29 examiners.
Titilayo Moloye has the most, with 2 of Baylor College of Medicine's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
